Zimmer Biomet (ZBH) Projected to Post Quarterly Earnings on Thursday

Zimmer Biomet (NYSE:ZBH - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $2.30 per share and revenue of $2.01 billion for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts' consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts' expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.65 EPS. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Stock Down 0.0 %

ZBH traded down $0.02 during trading on Thursday, reaching $111.03. The stock had a trading volume of 605,766 shares, compared to its average volume of 1,725,949. Zimmer Biomet has a one year low of $100.67 and a one year high of $133.90. The company has a market capitalization of $22.10 billion, a price-to-earnings ratio of 21.15, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock's 50 day moving average is $107.91 and its two-hundred day moving average is $108.22.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 18.25%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZBH. Stifel Nicolaus boosted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Raymond James cut their target price on Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. Wells Fargo & Company lifted their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Royal Bank of Canada increased their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, November 4th. Finally, Oppenheimer cut their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.